After adjusting for age at diagnosis, change in leucocyte count (standard laboratory technique; expressed as number x 109/L) one year after start of CBCT (leukocyte count one year after start – leucocytes count before chemotherapy), and PtAUC, we found associations between MetS prior to CBCT or developed within 5 years, and the change in global methylation (LINE-1), AC090023, NCAM2 and TOM1L2 (Table 1). This evidence concerns the gene TOM1L2 and metabolic syndrome.